Room: Commonwealth Hall

Poster Presenters noted with * are Student Fellows.



Presenting Tuesday through Thursday


Abcam, Inc.

101.     Multiplex miRNA Profiling for Biomarker Discovery and Verification Studies Using the FirePlex® Platform; Presented by Catherine T.

Abcam, Inc.

102.     Accelerating High-Throughput Screening with FirePlex®-HT: An Automatable, Multiplex Immunoassay Using FirePlex® Particle Technology; Presented by Catherine T.

Advanced Cell Diagnostics, Inc.

103.     Preclinical CAR-T Cell Target Safety, Biodistribution, and Tumor Infiltration Analysis Using In Situ Hybridization Technology; Presented by Christopher B.

Altis Biosystems, Inc.

104.     Predicting Chemotherapy-Induced Gut Toxicity In Vitro Using RepliGut Planar Human Small Intestinal Monolayer Cultures; Presented by Christopher S.

Aurelia Bioscience Ltd.

105.     Magnetic Electrospun Microfibre Scaffold Assemblies: Examples of Their Use for 3-Dimensional Cell-Based Screening Applications; Presented by Gary A.

Axion BioSystems, Inc.

106.     Multiwell Microelectrode Array Technology for Multimodal Characterization of Neural and Cardiac Networks In Vitro; Presented by Dan A.

Biognosys AG

107.     Characterization of Circulating Biomarkers in Subjects with NSCLC Using Data Independent Acquisition Mass Spectrometry Reveals Host Immune Response Mechanisms; Presented by Nicholas D.

Biognosys AG

108.     Limited Proteolysis Coupled to Mass Spectrometry (LiP-MS), a Novel Drug Target Deconvolution Strategy; Presented by Yuehan F.


109.     Significant Factors for Successful Formalin Fixed Paraffin Embedded Tissue Sample Prep for Downstream Applications; Presented by Nicole H.

Biomodels LLC

110.     Specific Reconstitution with A. muciniphila and E. hirae Human Commensal Microbes Impacts Mesenteric Lymph Node Immunophenotypic Response to PD-1 Inhibition Following Antibiotic and Radiotherapy Treatment in a Bioluminescent Orthotopic Model of Murine Lun; Presented by Benjamin C.

BrainXell, Inc.

111.     ALS Drug Discovery via High-Throughput Phenotypic Screening Using iPSC-Derived Human Motor Neurons; Presented by Michael H.

BrainXell, Inc.

112.     Spontaneous Calcium Oscillations of Networked Human iPSC-Derived Cortical Neurons as a Sensitive Model for Neurotoxicity Screening; Presented by Kurt L.

Caprion Biosciences, Inc.

113.     Targeted Mass Spectrometry for Biomarker Quantitation in FFPE Breast and Gastric Tumor Tissue Using the AQUA Approach; Presented by Anne J.

Chemical Computing Group

114.     Structure-Based Predictions of CYP Selectivity, Reactivity, and Regioselectivity; Presented by Alain A.

Chemical Computing Group

115.     MOEsaic: Application of Matched Molecular Pairs to Interactive SAR Exploration; Presented by Alain D.

Clarivate Analytics

116.     Bioinformatics Pipeline for Target ID and Indication Prioritization; Presented by Cheng F.

Concept Life Sciences

117.     Design and Validation of a Flow Cytometry Panel to Monitor Circulating Treg Frequencies as a PD Biomarker in Oncology or Autoimmune Disease; Presented by Nikola H.

Concept Life Sciences

119.     Development of a Specific Wee-1 Inhibitor; Presented by Andrew S.

Concept Life Sciences

120.     Interrogation and Modulation of the Immunosuppressive Activity of Human TAM-Like Macrophages Using In Vitro Cultures; Presented by Louise W.

CRO Centro di Riferimento Oncologico

121.     Characterizing Soluble E-Cadherin and HER2 Molecules in the Context of Gastric Cancer; Presented by Valli D.

Dana Farber Cancer Institute

122.     Improving the Ability of Hematopoietic Stem Cells in Generating Microglia-Like Progeny upon Transplantation; Presented by Annita M.*

Discovery Life Sciences

123.     Multiparametric Flow Cytometry Analysis of Checkpoint Inhibitors (PD-1 and PD-L1) in Dissociated Tumor and Normal Tissues; Presented by Shawn F.

Domainex Ltd.

124.     MAP4K4 Mediates Human Cardiac Muscle Cell Death: Preserving Viability and Function in Human Pluripotent Stem Cell-Derived Cardiomyocytes; Presented by Tom M.

Domainex Ltd.

125.     Identification of Antagonists of the Ion Channel TRPA1 Using a LeadBuilder Approach; Presented by Tom M.

Domainex Ltd.

126.     Design and Discovery of 3-Aryl-5-Substituted-Isoquinolin-1-Ones as Potent Tankyrase Inhibitors; Presented by Tom M.

Domainex Ltd.

127.     Fragment-Based Drug Design Using Microscale Thermophoresis; Presented by Tom M.

Domainex Ltd.

128.     Combinatorial Domain Hunting - Solving Target Protein Production Challenges; Presented by Tom M.

F. Hoffmann-La Roche AG

129.     Investigating Receptor Mediated Transcytosis with Advanced Blood-Brain Barrier Models; Presented by Roberto V.

Hamamatsu Photonics K.K.

130.     Comparing 2D Versus 3D Calcium Oscillations Using High-Throughput Fluorescence Measurement System (FDSS); Presented by Hirohumi H.

Harvard Medical School

131.     High Content Phenotypic Small Molecule Screen Reveals a Role of Endogenous H2S in DNA Damage Repair; Presented by Xiaofeng J.

Hybrigenics Services SAS

132.     Screening for Novel Chemically Induced Protein-Protein Interactions; Presented by Marie-Edith G.

immunoSCAPE, Inc.

133.     Simultaneous Identification and Profiling of Tumor-Specific T Cells by Mass Cytometry; Presented by David R.

King Faisal Specialist Hospital and Research Center

134.     Partial Loss in Sensitivity of Immunohistochemical Detection of PD-L1 in FFPE Compared to Frozen Tissues; Presented by Hazem G.

Korea Institute of Toxicology

135.     Comparison of Electrophysiological Properties in 2D and 3D Culture Models of Human iPS-Derived Cardiomyocytes; Presented by Hyang-Ae L.

Lonza Walkersville, Inc.

137.     Primary Human Hepatocyte Spheroid Generation and Performance in Different Culture Systems; Presented by Joseph C.

MedGenome, Inc.

138.     Applications of TCR Repertoire for Biomarker Discovery and Beyond; Presented by Ankita D.

Medicenna Therapeutics, Inc.

139.     Engineering a Long-Acting CD122 Biased IL-2 Superkine Displaying Potent Anti-Tumoral Responses; Presented by Moutih R.

Molecular Devices LLC

140.     Multi-Parametric Assessment of Compound-Induced Pro-Arrhythmic Effects in Human iPSC-Derived Cardiomyocytes; Presented by Oksana S.

NanoSurface Biomedical, Inc.

141.     Enhancing Pre-Clinical In Vitro Safety, Efficacy, and Discovery Assays with Structurally-Relevant iPSC-Cardiomyocyte Tissue Models in a High-Throughput Manner; Presented by Nicholas G.

Nanyang Technological University

142.     Tackling Antibiotics Crisis: Ribosome Protection Mechanism and Structure-Based Drug Design; Presented by Weixin S.*

National Institutes of Health, National Center for Advancing Translational Sciences

143.     Identifying New Drug Targets by Illuminating the Druggable Genome; Presented by Karlie S.


144.     High Throughput Phenotypic Efficacy Screening in a Diseased Model of Cardiac Hypertrophy Using hiPSC-Derived Cardiomyocytes; Presented by Stefan B.


145.     Controlled, Large Scale Manufacturing of hiPSC-Derived Cardiomyocytes in Stirred-Tank Bioreactors Enabling High Throughput Phenotypic Screening; Presented by Heather W.


146.     Expression Data Integration: Immuno-Oncology Biomarker Discovery and Validation; Presented by Natalie R.

NeuCyte, Inc.

147.     Implementation of Human iPSC-Derived Neural Cultures in CNS Drug Discovery; Presented by Daniel H.

Novartis Institutes for BioMedical Research

148.     Targeting IL-1b Pathway for Cancer Immunotherapy; Presented by Pushpa J.

Olink Proteomics, Inc.

149.     Plasma Proteomic Profiling for Prediction of Immunotherapy Response and Toxicity; Presented by Marijana R.

ONI Ltd.

150.     Quantitative Imaging and Phenotyping of EVs with 20 nm Resolution; Presented by Valerio P.

ONI Ltd.

151.     Single-Molecule Fluorescence Imaging for Drug Discovery, Target Validation, and Drug Distribution Analysis in Cells and Tissue; Presented by Valerio P.

Otsuka Pharmaceutical Co., Ltd.

152.     Development of the Target Identification Method Directing to Plasma Membrane from Live Tissue; Presented by Yuki O.


153.     Translational Immuno-Oncology: Use of Humanized Mouse and Human Tissue Based Models in Preclinical Research; Presented by Yuan Z.

PointCross Life Sciences

154.     Considerations for Integrating Clinical and Biomarker Data for Research and Cohort Selection; Presented by Christopher M.

ProQinase GmbH

155.     Novel PDX-Like Syngeneic Tumor Models Featuring Conserved Stroma Profiles; Presented by Katrin S.

PsychoGenics, Inc.

156.     Novel Approaches for Drug Discovery Using High Throughput In Vivo Analysis System; Presented by Taleen H.


157.     Development of a High Sensitivity 10-Plex Human Cytokine Assay Using Simoa Planar Array Technology; Presented by Purvish P.

Samsung Biomedical Research Institute

158.     Establishment and Characterization of Patient-Derived Organotypic Tumor Spheroid (PDOTS) Models for the Tumor Immune Microenvironment Modelling; Presented by Hye Kyung H.

Seoul National University

159.     Tumor Spheroid-on-a-Chip: A Standardized Microfluidics Platform for Investigating Tumor Angiogenesis; Presented by Jihoon K.*

Seoul National University

160.     Reconstituting 3D Human Lymphatic Tumor Microenvironment on High-Throughput Microfluidic Chip for Studying Lymphatic Recirculation; Presented by Somin L.*

Seoul National University

161.     Reconstitution of the Tumor Microenvironment in a Microfluidic Platform Comprising a Bone-Mimetic Hydroxyapatite/Fibrin Composite; Presented by Jungeun L.*

Takara Bio USA, Inc.

162.     Development of a Next-Generation Hepatocyte Medium that Increases the Viability and Functionality of Human Primary and iPS Cell-Derived Hepatocytes for Long-Term Studies; Presented by Liz Q.

Technische Universitat Berlin

163.     Modeling the Neurovascular Niche in an Autologous Stem Cell Derived 4-Organ-Chip; Presented by Leopold K.*

TNO - Netherlands Organisation for Applied Scientific Research

164.     Development of a Diet-Induced Disease-Mimicking In Vitro Model of Non-Alcoholic Steatohepatitis (NASH)/ Fibrosis; Presented by Ivana B.

TNO - Netherlands Organisation for Applied Scientific Research

165.     Further Development of TargetTri: A Toxicity-Based Triaging System for Novel Drug Targets; Presented by Simon F.

Toppan Printing Co. Ltd.

166.     A Layered 3D Stromal Tissue Model Ideal for (Immuno-) Oncology Drug Screening; Presented by Isana N.

Universidade de Lisboa

167.     Highly Specific Blood-Brain Barrier Single-Domain Antibodies Selected by In Vivo Phage Display Screenings; Presented by Frederico A.

Universidade de Lisboa

168.     Single-Domain Antibodies and Canine Lymphoma Model as a Promising Approach to Develop Potent Antibody-Drug Conjugated Compounds; Presented by Frederico A.

Université de Montréal

169.     Optimization of a Microfluidic System for High-Throughput Screening of Combinations of Drugs with Radiotherapy on Spheroids; Presented by Maeva B.*

University of Copenhagen

170.     DNBseq™, a Proven and Robust High-Throughput Next-Generation Sequencing Technology; Presented by Zonghui P.*

Visiopharm A/S

171.     A Novel Method for High Parameter Multiplex Phenotyping and Analysis of the Tumor Micro-Environment; Presented by Regan B.

Applied StemCell, Inc.

172.     A Site-Specific, Controlled Copy Number, Integrase Platform for Mammalian Protein Library Screening; Presented by Andrew J. H.

SUNY Upstate Medical University

173.     Stepping into the Light: Translational Potential of Relaxin-3 and a Novel Stapled Peptide in Neuropsychiatric Disorders; Presented by Subhi M.


174.     Screening for Potential Therapeutics Against Neurodevelopmental Disorders Using a 3-Dimensional Human Cortical Neural Platform; Presented by Fabian Z.

EPAM Systems

175.     Med3web Viewer and Editor; Presented by Paul T.

EPAM Systems

176.     Miew; Presented by Paul T.

DefiniGEN Ltd.

177.     Modelling PNPLA3 Induced Non-Alcoholic Fatty Liver Disease Using iPS-Derived Hepatocytes; Presented by Marcus Y.


178.     Predictive Models for Assessing Risk of Adverse Events from Molecular Structure; Presented by Eric G.

Proteome Sciences Plc

179.     A Novel Method for Discovery of Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis Using Extensive Depletion and TMTcalibrator™ Tissue-Enhanced Plasma Proteomics; Presented by Richard D.

Sygnature Discovery

180.     Structurally-Enabled Progression of Novel Fragment Hits for the Epigenetic Target BRD3; Presented by Bill M.

Sygnature Discovery

181.     Validation of Ex Vivo Autoradiographic Techniques to Quantify ต and κ Opioid Receptor Occupancy in Rat Brain Regions Using Morphine, Buprenorphine and (-)-Pentazocine; Presented by Nick M.

Sygnature Discovery

182.     Characterisation of In Vitro Models of Microglia Function to Support Neuroinflammation Drug Discovery; Presented by Nick M.

Cellecta, Inc.

183.     Combining Cell Barcoding and CRISPR sgRNA Libraries with Targeted Gene Expression for Single-Cell Genetic Analysis of Tumor Progression; Presented by Paul D.

MBL International Corporation

184.     Regulation of PD-L1 Expression in Stimulated Antigen-Specific CD8+ T Cells by the Immunoglobulin 4 (IgG4); Presented by Mamunur R.



Presenting Tuesday through Wednesday (morning)


Arizona State University

201.     Nanoplasmonic Quantification of Tumor-Derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring; Presented by Meryl R.*

Genedata, Inc.

202.     Digitalization of Translational Research to Facilitate Efficient Development of Precision Medicines; Presented by David K.

Life Chemicals, Inc.

203.     Novel Fragment Libraries from Life Chemicals; Presented by George B.

Life Chemicals, Inc.

204.     Screening Compound Libraries for HTS and Lead Discovery Projects; Presented by George B.

Metrion Biosciences Ltd.

205.     Potent and Selective State-Dependent Cav2.2 Calcium Channel Modulators with Analgesic Efficacy in Preclinical Animal Models and Human Tissue; Presented by Marc R.

NovoVita Histopath Lab LLC

206.     Robust, Reliable, and Cost-Effective Biomarker Development with NovoVita Histopath; Presented by Andrew H.

West Virginia University

207.     Novel Use of the 'Photosensitivity Model of Epilepsy' to Identify the Rapidity of Anti-Epileptic Drug (AED) CNS Effect: Implications for Treatment of Acute Repetitive Seizures; Presented by Ronald R.



Presenting Wednesday (afternoon) through Thursday


Genedata, Inc.

301.     Translation of a Standardized and Compliant Bioinformatics Analysis Pipeline from Research to Clinical Trials; Presented by Marcell V.

Nanion Technologies, Inc.

302.     Parallel Cytotoxicity and Safety Assessment Monitoring Using Human iPSC Cardiomyocytes and Cancer Cells; Presented by Ronald K.

Nektar Therapeutics

303.     Discovery of Potent, Selective, and Orally Bioavailable Adenosine A2a Receptor Antagonists for Immuno-Oncology; Presented by Donogh O.

Newcastle University

304.     Development of a Predictive In Vitro Primary Proximal Tubule Platform for De-Risking Nephrotoxicity Testing; Presented by Colin B.


305.     Machine Learning-Driven Image-Based Pooled Screening; Presented by Waichiro K.